{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:26:00Z","timestamp":1768004760788,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Takeda"},{"name":"Otsuka"},{"DOI":"10.13039\/100006399","name":"Spectrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000555","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pharmacyclics"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clml.2018.11.010","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T19:43:24Z","timestamp":1542051804000},"page":"95-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen"],"prefix":"10.1016","volume":"19","author":[{"given":"Nirav N.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raya","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Strelec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dheeraj","family":"Kodali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olukemi","family":"Esan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony R.","family":"Mato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham S.","family":"Kanate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horatiu","family":"Olteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.11.010_bib1","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.010_bib2","first-page":"740","article-title":"Current treatment approaches in follicular lymphoma","volume":"13","author":"Kahl","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2018.11.010_bib3","doi-asserted-by":"crossref","first-page":"e0177204","DOI":"10.1371\/journal.pone.0177204","article-title":"Impact of treatment in long-term survival patients with follicular lymphoma: a Spanish Lymphoma Oncology Group registry","volume":"12","author":"Provencio","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.11.010_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.010_bib5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.010_bib6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.5858\/2007-131-1084-GOFLCO","article-title":"Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry","volume":"131","author":"Martinez","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2018.11.010_bib7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.010_bib8","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clml.2018.11.010_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2014.04.008","article-title":"Follicular lymphoma grade 3: review and updates","volume":"14","author":"Vaidyanathan","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.11.010_bib10","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood.V110.11.2611.2611","article-title":"Grading follicular lymphoma: no difference between 1, 2 and 3A, but 3B is something else","volume":"110","author":"Wahlin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.010_bib11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.010_bib12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.11.010_bib13","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.010_bib14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.010_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.010_bib16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2011.050930","article-title":"Follicular lymphoma grade 3B: is it a real disease?","volume":"96","author":"Harris","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.010_bib17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.010_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.11.010_bib19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.1994.12.7.1349","article-title":"Follicular large-cell lymphoma: intermediate or low grade?","volume":"12","author":"Bartlett","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.010_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.11.010_bib21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdl039","article-title":"Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group experience","volume":"17","author":"Ganti","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.11.010_bib22","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/annonc\/mdq574","article-title":"Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy","volume":"22","author":"Shustik","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.11.010_bib23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2017.07.002","article-title":"Grade 3 follicular lymphoma: outcomes in the rituximab era","volume":"17","author":"Mustafa Ali","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.11.010_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","article-title":"Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study","volume":"23","author":"Mondello","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2018.11.010_bib25","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","article-title":"Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin\u2019s lymphoma","volume":"23","author":"Schoder","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.010_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.11.010_bib27","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2014-11-537522","article-title":"FDG PET-CT in follicular lymphoma: a case-based evidence review","volume":"125","author":"Smith","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.010_bib28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3324\/haematol.12013","article-title":"Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma","volume":"93","author":"Bodet-Milin","year":"2008","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:54Z","timestamp":1761870714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018311868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2152265018311868"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}